Iradimed Corp (IRMD) VP Brent Johnson Sells 3,000 Shares

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 3,000 shares of the business’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $21.83, for a total transaction of $65,490.00. Following the sale, the vice president now owns 4,368 shares in the company, valued at $95,353.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Brent Johnson also recently made the following trade(s):

  • On Monday, May 20th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $22.53, for a total transaction of $45,060.00.
  • On Wednesday, March 13th, Brent Johnson sold 52,492 shares of Iradimed stock. The stock was sold at an average price of $24.42, for a total transaction of $1,281,854.64.
  • On Monday, March 11th, Brent Johnson sold 17,033 shares of Iradimed stock. The stock was sold at an average price of $25.38, for a total transaction of $432,297.54.
  • On Wednesday, March 6th, Brent Johnson sold 9,672 shares of Iradimed stock. The stock was sold at an average price of $24.58, for a total transaction of $237,737.76.

Shares of Iradimed stock traded up $0.89 on Tuesday, hitting $21.99. The company’s stock had a trading volume of 49,689 shares, compared to its average volume of 64,603. Iradimed Corp has a 52-week low of $18.20 and a 52-week high of $38.78. The company has a quick ratio of 8.63, a current ratio of 9.48 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $251.14 million, a PE ratio of 51.14 and a beta of 1.70.

Iradimed (NASDAQ:IRMD) last released its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.11 EPS for the quarter, hitting the consensus estimate of $0.11. Iradimed had a net margin of 23.00% and a return on equity of 13.98%. The business had revenue of $8.44 million for the quarter, compared to analyst estimates of $8.38 million. On average, research analysts expect that Iradimed Corp will post 0.64 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in Iradimed during the first quarter worth $241,000. Charles Schwab Investment Management Inc. bought a new position in Iradimed during the first quarter worth $221,000. Renaissance Technologies LLC lifted its stake in Iradimed by 8.0% during the first quarter. Renaissance Technologies LLC now owns 346,200 shares of the medical equipment provider’s stock worth $9,725,000 after purchasing an additional 25,700 shares during the last quarter. AQR Capital Management LLC lifted its stake in Iradimed by 73.4% during the first quarter. AQR Capital Management LLC now owns 15,764 shares of the medical equipment provider’s stock worth $443,000 after purchasing an additional 6,673 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Iradimed by 56.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 13,188 shares of the medical equipment provider’s stock worth $370,000 after purchasing an additional 4,780 shares during the last quarter. Institutional investors and hedge funds own 21.58% of the company’s stock.

Several equities research analysts recently commented on the stock. BidaskClub upgraded shares of Iradimed from a “hold” rating to a “buy” rating in a research report on Friday, February 8th. Zacks Investment Research lowered shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Finally, ValuEngine lowered shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $31.50.

ILLEGAL ACTIVITY WARNING: “Iradimed Corp (IRMD) VP Brent Johnson Sells 3,000 Shares” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2019/05/21/iradimed-corp-irmd-vp-brent-johnson-sells-3000-shares.html.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Read More: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.